APO-SITAGLIPTIN MALATE / METFORMIN HYDROCHLORIDE

, 7 WARNINGS AND PRECAUTIONS, Endocrine and Metabolism and 7 WARNINGS AND PRECAUTIONS, and Special Populations). 2 CONTRAINDICATIONS  Unstable and/or insulin-dependent (type 1) diabetes mellitus.  Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma, history of ketoacidosis with or without coma.

 In patients with a history of lactic acidosis, irrespective of precipitating factors (see 7 WARNINGS AND PRECAUTIONS). 73 m2)], end-stage renal disease, in patients on dialysis or when renal function is not known (see 7 WARNINGS AND PRECAUTIONS).

 In excessive alcohol intake, acute or chronic. APO-SITAGLIPTIN MALATE / METFORMIN HYDROCHLORIDE Page 5 of 68 Sitagliptin and metformin hydrochloride tablets  In patients suffering from severe hepatic dysfunction, since severe hepatic dysfunctio n has been associated with some cases of lactic acidosis, APO-SITAGLIPTIN MALATE / METFORMIN HYDROCHLORIDE should not be used in patients with clinical or laboratory evidence of hepatic disease.

 In cases of cardiovascular collapse and in disease states associated with hypoxemia such as cardiorespiratory insufficiency, which are often associated with hyperlactacidemia.  During stress conditions, such as severe infections, trauma or surgery and the recovery phase thereafter.

 In patients suffering from severe dehydration or shock.  Known hypersensitivity to sitagliptin, metformin or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container (see 7 WARNINGS AND PRECAUTIONS and 8 ADVERSE REACTIONS).

For a complete listing, see the

). For a complete listing, see the 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING section.  During pregnancy and breastfeeding (see 7 WARNINGS AND PRECAUTIONS, Special populations).  During period around administration of iodinated contrast materials, because the use of such products may result in acute alteration of renal function (see 7 WARNINGS AND PRECAUTIONS).

3 SERIOUS WARNINGS AND PRECAUTIONS BOX Serious Warnings and Precautions Lactic Acidosis  Lactic acidosis is a rare, but serious, metabolic complication that can occur due to metformin accumulation during treatment with APO-SITAGLIPTIN MALATE / METFORMIN HYDROCHLORIDE (see 7 WARNINGS AND PRECAUTIONS, Endocrine and Metabolism – Lactic Acidosis).

 Patients should be cautioned against excessive alcohol intake, either acute or c hronic, when taking APO-SITAGLIPTIN MALATE / METFORMIN HYDROCHLORIDE, since alcohol intake potentiates the effect of metformin on lactate metabolism (see 7 WARNINGS AND PRECAUTIONS, Endocrine and Metabolism – Lactic Acidosis).

1 Dosing Considerations  The dosage of APO-SITAGLIPTIN MALATE / METFORMIN HYDROCHLORIDE should be individualized on the basis of the patient’s current regimen, effectiveness, and tolerability while not exceeding the maximum recommended daily dose of 100 mg sitagliptin and 2000 mg metformin hydrochloride.

Dose escalation should be gradual to reduce the gastrointestinal side effects associated with metformin use. Factors that may increase the risk of lactic acidosis should be reviewed before considering initiation of metformin-containing products in patients with renal impairment.

73 m2 is 50 mg and 1000 mg, respectively. , sulfonylurea), a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia (see 7 WARNINGS AND PRECAUTIONS and 8 ADVERSE REACTIONS).  Concomitant Use with Medication(s) that May Decrease Renal Function Caution should be exercised when using concomitant medication(s) that may decrease renal function (like diuretics, particularly loop diuretics) or may interfere with the disposition of metformin, such as cationic drugs, that are eliminated by renal tubular secretion, due to the increased risk of developing lactic acidosis during co - administration (see

, Endocrine and Metabolism and 7 WARNINGS AND PRECAUTIONS, and Special Populations). 2 CONTRAINDICATIONS  Unstable and/or insulin-dependent (type 1) diabetes mellitus.  Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma, history of ketoacidosis with or without coma.

 In patients with a history of lactic acidosis, irrespective of precipitating factors (see 7 WARNINGS AND PRECAUTIONS). 73 m2)], end-stage renal disease, in patients on dialysis or when renal function is not known (see 7 WARNINGS AND PRECAUTIONS).

 In excessive alcohol intake, acute or chronic. APO-SITAGLIPTIN MALATE / METFORMIN HYDROCHLORIDE Page 5 of 68 Sitagliptin and metformin hydrochloride tablets  In patients suffering from severe hepatic dysfunction, since severe hepatic dysfunctio n has been associated with some cases of lactic acidosis, APO-SITAGLIPTIN MALATE / METFORMIN HYDROCHLORIDE should not be used in patients with clinical or laboratory evidence of hepatic disease.

 In cases of cardiovascular collapse and in disease states associated with hypoxemia such as cardiorespiratory insufficiency, which are often associated with hyperlactacidemia.  During stress conditions, such as severe infections, trauma or surgery and the recovery phase thereafter.

 In patients suffering from severe dehydration or shock.  Known hypersensitivity to sitagliptin, metformin or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container (see 7 WARNINGS AND PRECAUTIONS and

 Unstable and/or insulin-dependent (type 1) diabetes mellitus.  Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma, history of ketoacidosis with or without coma.  In patients with a history of lactic acidosis, irrespective of precipitating factors (see 7 WARNINGS AND PRECAUTIONS).

73 m2)], end-stage renal disease, in patients on dialysis or when renal function is not known (see 7 WARNINGS AND PRECAUTIONS).  In excessive alcohol intake, acute or chronic. APO-SITAGLIPTIN MALATE / METFORMIN HYDROCHLORIDE Page 5 of 68 Sitagliptin and metformin hydrochloride tablets  In patients suffering from severe hepatic dysfunction, since severe hepatic dysfunctio n has been associated with some cases of lactic acidosis, APO-SITAGLIPTIN MALATE / METFORMIN HYDROCHLORIDE should not be used in patients with clinical or laboratory evidence of hepatic disease.

 In cases of cardiovascular collapse and in disease states associated with hypoxemia such as cardiorespiratory insufficiency, which are often associated with hyperlactacidemia.  During stress conditions, such as severe infections, trauma or surgery and the recovery phase thereafter.

 In patients suffering from severe dehydration or shock.  Known hypersensitivity to sitagliptin, metformin or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container (see 7 WARNINGS AND PRECAUTIONS and 8 ADVERSE REACTIONS).

For a complete listing, see the 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING section.  During pregnancy and breastfeeding (see 7 WARNINGS AND PRECAUTIONS, Special populations).  During period around administration of iodinated contrast materials, because the use of such products may result in acute alteration of renal function (see 7 WARNINGS AND PRECAUTIONS).